CLINICAL_TRIALS trial_result · 2017-06-29

Clinical Trial Update: Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC [Phase 2]

Phase 2 clinical trial update for SNS-595 as second-line therapy in advanced non-small cell lung cancer (NSCLC) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Sunesis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2017-06-29